Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of cevostamab combinations in relapsed or refractory multiple myeloma
jRCT2041260039Phase 3Recruiting
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Jul 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, open-label trial of cevostamab, pomalidomide, dexamethasone, daratumumab, recombinant human hyaluronidase PH20 and 2 more in multiple myeloma (MM) (4 arms), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoints: MRD-negative complete response rate and Progression-free survival. Started Jul 2026; status: recruiting.
02
Drugs
cevostamabpomalidomidedexamethasonedaratumumabrecombinant human hyaluronidase PH20
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on jRCT2041260039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041260039.